glp-1 sleep apnea trial glp 1 GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Efficacy and safety of GLP-1

Depression and metabolic syndrome in the older population: a review of evidence

States will announce participation decisions in mid-2026

GLP-1 medications are recommended in the ADA Standards of Care for those with cardiovascular disease, heart failure, and/or kidney disease to reduce the risk of adverse events due to these conditions

Pham TK, Nguyen THT, Yun HR, Vasileva EA, Mishchenko NP, Fedoreyev SA, et al

This avoids the weight regain risk of a full drug holiday

Most bruises associated with semaglutide injections are small (less than one inch in diameter), painless or mildly tender, and resolve within 7-14 days without treatment